martes, 29 de enero de 2019

In disappointment, Bristol pulls application for Opdivo combo in lung cancer

In disappointment, Bristol pulls application for Opdivo combo in lung cancer

Cancer Briefing

STAT Plus: In disappointment, Bristol pulls FDA application for Opdivo combination in lung cancer

By MATTHEW HERPER


MEL EVANS/AP
The company now says that it will need more data to explain outcomes in clinical trials, and wants to discuss data based on another test, for PD-L1.

No hay comentarios: